AQR Capital Management
TARA icon

AQR Capital Management’s Protara Therapeutics TARA Stock Holding History

AQR Capital Management’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$348K Buy
66,805
+52,124
+355% +$309K ﹤0.01% 3335
2025
Q4 		$78.3K Buy
+14,681
New +$81.6K ﹤0.01% 3479

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

AQR Capital Management's TARA Position: Q1 2026 in Review

AQR Capital Management increased its Protara Therapeutics (TARA) stake by 355% in Q1 2026, buying an estimated $309K and bringing the position to 66,805 shares worth $348K. The position accounts for ﹤0.01% of the portfolio, ranked #3335.

AQR Capital Management first reported a position in TARA in Q4 2025 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

  • AQR Capital Management held 66,805 shares of Protara Therapeutics worth $348K as of Q1 2026.
  • AQR Capital Management bought 52,124 Protara Therapeutics shares in Q1 2026, an estimated $309K.
  • Protara Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #3335 holding.
  • AQR Capital Management first reported a position in Protara Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.